As we all know, humans evolve from animals, whose anatomical and structs are related to mammal animals.However, the habits between them are different, especially upright walking and sleeping on your back.Animals appeared earlier than humans, so physiological habits animals ， physiological habits may be more in line with the laws of nature, which may lead to the use of some organs or systems of human beings not in line with the laws of natural evolution.In fact, humans often suffer from some common chronic diseases that rarely occur in animals.Such as varicocele and prolapse of inter-vertebral disc, this phenomenon may be related to the human ' s position of special activities and rest.For example, the standing position increases gravity load of the lumbar disc and increases the distance of blood drainage from the spermatic venous, while sleeping on your back aggravates the compression on the spermatic venous.In addition, a series of clinical medical studies prove that sleeping on your back is more harmful compared to sleeping on your side in a variety of disease states These modern medical evidence well support a point in traditional Chinese medicine: it is better to sleep on your side This paper aims to deepen the understanding of traditional Chinese medicine (TCM) and the etiology of some common chronic diseases from the perspective of comparative anatomy between human beings and mammals.
Objectives: CIMAvax-EGF is a therapeutic vaccine registered as switch maintenance therapy.This vaccine induces antibodies against self EGF that affect EGF-EGFR interaction.The aim of this study was to evaluate safety and efficacy of CIMAvax-EGF in the context of primary care. Methods:A phase IV clinical trial was conducted in 65 Policlinic areas and 16 hospitals in Cuba during 3 years.A total of 1081 advanced NSCLC patients were included without other treatment options due to progressive disease or comorbidities.CIMAvax-EGF was administered by intramuscular injection in four sites of administration (4 subdoses of 0.25 ml), every 2 weeks the first 4 doses and after this induction phase monthly reinmunizations were given.Results: A total of 927 patients (85.7 %) received at least one dose of CIMAvaxEGF.Most frequently adverse events related to vaccine were: injection-site reaction (14.5%), fever (7.0%), headache (5.8%), tremors (4.3%), and nausea (4.3%).Most of them were grade1 -2 according CTCAE v3.There were no deaths related to CIMAvaxEGF.The median overall survival (mOS) time for all vaccinated patients was 7.0 months, and in a subgroup of patient who received at least 4 doses of CIMAvaxEGF mOS was 9.98 months (n=715).Patients treated as switch maintenance therapy (n=97) reached a mOS of 12.1 months.In a subgroup of unfit patients (n=213) mOS was 3.97 months, but in those who completed the induction phase mOS was 7.36 months (n=124).Emotional function was improved at months 6 and 12 compared to baseline. Conclusions:CIMAvaxEGF vaccine is a safe treatment option for advanced NSCLC that can be safely administered at primary level of health care.The median OS of treated patients (unselected population) compares with the results reported for second-line treatments and switch maintenance therapies.Patients who completed the induction phase of the treatment reached a better OS.
The APPIRED II study is a randomized controlled phase II clinical study that was set up to test the anti-inflammatory effects of intervenously-dosed bRESCAP in 53 patients undergoing cardiac surgery.bRESCAP is a specific type of bovine intestinal alkaline phosphatase that is currently under development as a biological response modifier for the treatment of various inflammatory diseases.Patients undergoing cardiac surgery are at increased risk to develop a systemic inflammatory response syndrome (SIRS).This syndrome may lead to death by downstream complications like multi-organ failure.In a previous study among patients undergoing coronary artery bypass grafting, it was demonstrated that bRESCAP diminishes the cytokine storm which appeared to be initiated by a significant TNFa response.The current APPIRED II study was set up to further extend these findings in a population of cardiac surgery patients with a higher chance to die from surgery.In APPIRED II, however no significant TNF alpha response occurred.Various other inflammatory markers in plasma of patients were temporarily increased upon surgery but did not respond to bRESCAP treatment.Safety-wise, APPIRED II was successful.No statistically significant differences were observed between placebo treated and bRESCAP treated patients with respect to inflammatory cytokines, haematology, clinical chemistry, cardiac function, body temperature, hospitalization time and the total number of adverse effects.Perioperative mortality was absent in the bRESCAP group.In the placebo group, the perioperative mortality was 12% (n.s.).From the data of the APPIRED II study it can be concluded that short term intravenous treatment of cardiac surgery patients with bRESCAP is safe.Potential TNF alpha lowering effects of bRESCAP treatment could not be demonstrated in this study as no TNF alpha dependent inflammatory responses were observed in any of the patients.
Received: January 20, 2020; Accepted: February 04, 2020; Published: February 10, 2020 It is not common for papers on plant hormones to find their way into any endocrinological journals. Plants and mammals seem as far apart biologically as one could get. But in a number of respects animal and plant hormones do share some common issues in which knowledge in one can help better understanding of the other.
